We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Berkeley Scot | LSE:BGP | London | Ordinary Share | GB00B03W5P29 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 22.59 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/2/2002 19:39 | Does anyone know what effect the potential buy out is going to have on the stock price as it seats at the moment? | xnews | |
07/2/2002 11:45 | All gone a bit quiet again, anyone got opinions on deal with quintiles, or with a third party whoever they may be. And what has the sale of bristol myers squib got to do with bioglan. | dryboy | |
05/2/2002 18:56 | Does the CEO of Enron have one arm and go by the name of Richard Kimble ? | stampcoverman | |
05/2/2002 17:06 | For a bust company, there seems to be a lot of 'Buys' going on. Anybody know why ? | stampcoverman | |
04/2/2002 11:14 | Suspect we'll see Deutsche dump the rest of their holding at whatever they can get. Only 2.5 million to go! Wonder who's buying them?? | wetdream | |
04/2/2002 10:13 | I haven't watched Coronation Street since 1964, so I doubt if I would find much time to watch 'Einstein TV'. Anyway, we all know that the only thing worth watching is Star Trek................ | stampcoverman | |
04/2/2002 07:11 | Found this over the w/e, possibly the best 2002 recovery share. | easyramp | |
03/2/2002 23:53 | Yes, it must be worth it for Mr.Sadler to do something for the share holders seeing as he has most to lose. I would like to know if there is any real chance of Bioglan reducing any of its debt mountain by its own turnover (without any outside help), even if it takes a long time. | stampcoverman | |
02/2/2002 00:21 | what planet are you guys on? if the level of the offer was equal to the comapanies debt, shareholders would get nothing. the RNS is saying that it looks likely that if an offer was made then it would be for a nominal value, probably a few pence. | dr biotech | |
01/2/2002 21:53 | if somebody sells somebody else buys, so somebody bought 1000000 shares at 7p there still is hope, if they pay 113 million they can pay 8/10 million more to satisfy shareholders that by now thing they lost everyting hense 10p . | terropol | |
01/2/2002 20:42 | Ironic thing was that ADVFN showed the 1m trade as a buy! Lesson 1 - never trust the trade info. | wetdream | |
01/2/2002 19:18 | sod it i cant find the switch, and mali7 has nicked the last life jacket. | lovegod | |
01/2/2002 17:51 | LONDON (AFX) - A Bioglan Pharma PLC share issue would probably create some share price weakness, but this would represent a strong buying opportunity, according to WestLB Panmure analyst Emma Palmer. A press report that Bioglan's institutional shareholders are putting pressure on the company to make a 200 mln stg share issue to fund the acquisition of Bristol-Myers Squibb's skin-care arm saw Bioglan's shares fall to 390 pence at the outset. By 11.04 am, however, the stock had rallied to show a gain of a 1/2 at 398 as dealers adopted a more positive stance on a possible share issue. The 484 mln stg acquisition would give the company a much bigger presence in the US and turn it into one of the UK's largest independent drugs companies. The company's plan to finance the deal via increased borrowing, however, has triggered worries about the resulting high level of debt. Since the deal has not yet been finalised -- and there are no guarantees that it will happen -- there are no details and any comments made are speculative, said Palmer. However, since the number of shares needed for the suggested 200 mln usd upfront payment would increase issued capital by a third at present levels, the analyst expects there to be some price weakness and believes that this represents a strong buying opportunity. An initial payment of 200 mln usd would increase gearing to 167 pct from the current level of 60 pct. The press rumours suggest that institutional investors are unhappy with this level of gearing and are instead pressurising the company to issue new shares. fjb/jsa For more information and to contact AFX: www.afxnews.com and www.afxpress.com Bioglan Pharma(BGP) GB0004342670 C(p) -1.25 C(%) -19.231 C 5.25 B 5.0 O 5.5 H 6.25 L 4.75 Op 5.75 V 3,238,599 T close A GOOD CALL EMMA. | sjc | |
01/2/2002 17:13 | Latest RNS confirms that the ship is, glug,glug,indeed sinking! Deutsche sold 1m @7p - and they should know! Last one to leave please turn out the lights.. | wetdream | |
01/2/2002 16:17 | i think we all need a nice cuppa tea | rioleatapas | |
01/2/2002 15:57 | The shares are still trading and the price is down. What exactly about this does anybody not understand? If the news was good the price would rise If the news is bad the price will fall This does not take a rocket scientist! | salpara111 | |
01/2/2002 15:31 | Can't really see the point of Quintiles buying Bioglan lock stock and barrel - they're a thrid party CRO and a CSO - not a manufacturing co. They might be keen to expand into marketing where margins are higher(hence SKP's Solaraze in the US) but they've no pharma products of their own. So a 30% stake would make more sense. | wetdream | |
01/2/2002 14:31 | I think what they get is a 30% stake in a growing company. Bioglan are only in a mess because their debt is too high. If Quintiles or any other 3rd party has got spare cash, this company has got long term growth prospects. | stampcoverman | |
01/2/2002 14:19 | Again, what is in that for Quintiles? If they can pick up the whole company for the cost of the debt, why would they agree to effectively subsidise the private shareholders by paying off debt? You need to think about this from their perspective, not ours. They really don't care whether we are happy or not, they simply want a reasonable business (which Bioglan is when the debt is removed) for as little money as possible. Much like us, in fact. Paul DSP | paul dsp |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions